ClinicalTrials.gg
CompletedNCT00806728Updated Dec 11, 2008

Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease

A Phase 1 interventional study of MEDI-507 and MEDI-507 in Cancer and Graft-Versus-Host Disease, sponsored by MedImmune LLC. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-12-11.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A clinical trial to assess safety and two regimens of (MEDI-507) a drug given to stem cell and bone marrow recipients who have a mid-grade acute Graft-versus-Host Disease.

Read the detailed description

To assess the safety of two regimens of MEDI-507 administered to stem cell and bone marrow allograft recipients who have at least grade II acute GVHD and who have not achieved a satisfactory response to at least three days of corticosteroid therapy (2 mg/kg/day of methylprednisolone or its equivalent).

02

Conditions studied

  • Cancer
  • Graft-Versus-Host Disease
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 17 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.

First submitted after MedImmune LLC became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Allogeneic bone marrow or hematopoietic stem cell graft recipients
  • Acute of at least grade II severity
  • Failure of GVHD to improve on at least 2 mg/kg/day of methylprednisolone or prednisone for at least three days or recurrence of acute GVHD as are tapered from initial treatment of the initial episode of GVHD
  • Evidence of engraftment (ANC over 1000 cells/mm3)
  • Histologic evidence of GVHD from performed during the current episode
  • Received GVHD prophylaxis of methotrexate, tacrolimus or cyclosporine
  • Age at least 18 years
  • Body weight under 130 kg
  • Both males and females are eligible but females of will use an accepted method of avoiding pregnancy for at least 60 days after the end of treatment (which includes oral or implanted , IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or a sterile sexual partner)

Exclusion criteria

Exclusion Criteria:

  • Previous receipt of MEDI-507
  • Clinical or histologic manifestation of chronic
  • Previous treatment with any anti-T-cell antibodies such as OKT®3 or daclizumab (Zenapax®)
  • Receipt of antithymocyte globulin (ATGAM® or other ATG) since the day of transplant
  • More than one allogeneic bone marrow or hematopoietic stem cell allograft
  • Moribund and unlikely (in the opinion of the investigator) to survive 15 days
  • Use of other agents within 30 days (this does not include the use of licensed agents for indications not listed in the package insert)
  • Any of the following clinical settings or diagnoses:

Ø documented or presumed significant active infection Ø pregnancy or nursing mother Ø evidence of infection with -1, or C virus Ø hemodialysis or chronic peritoneal dialysis Ø use of a ventilator

  • confirmed veno-occlusive disease of the liver
  • Ascites on physical examination (this does not include small amounts of ascitic fluid detected only on ultrasound)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    1

    MEDI-507

    Drug: MEDI-507

  • Experimental
    2

    MEDI-507

    Drug: MEDI-507

Interventions

  • 0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.

  • 0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of MEDI-507 on Days 16, 23, 30, and 37.

06

What researchers measure

Primary outcomes

  1. Safety was assessed by the direct observation of patients, medical history, and clinical laboratory evaluation to determine the incidence of patients experiencing AEs.

    Time frame: Day 0-60

Secondary outcomes

  1. Pharmacokinetics, Lymphocyte Phenotype and CD2 Receptor Occupancy Pharmacodynamics

    Time frame: Study Days 12 and 44

07

Study locations

10 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • University of Colorado Health Sciences Center
    Denver, Colorado 80262, United States
  • University of Michigan Hospital
    Ann Arbor, Michigan 48109, United States
  • Washington University Medical Center
    St. Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • University Hospital-University of Oklahoma
    Oklahoma City, Oklahoma 73104, United States
  • Western Pennsylvania Hospital - Western Pennsylvania Cancer Center
    Pittsburgh, Pennsylvania 15224, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • South Texas Cancer Institute at Methodist Hospital
    San Antonio, Texas 78229, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 1998, a primary completion of Nov 1998 and a completion of Dec 1998. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2008
First posted
Dec 11, 2008
Start
May 1998
Primary completionActual
Nov 1998
CompletionActual
Dec 1998
Last update
Dec 11, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00806728
Lead sponsor
MedImmune LLC
First posted
Dec 11, 2008
Start date
May 1998
Primary completion
Nov 1998
Completion
Dec 1998
Last update
Dec 11, 2008

Study contacts

J. Bruce McClain, M.D.
study director · MedImmune LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siplizumab

Start the discussion